APA (7th ed.) Citation

Decaens, T., Kudo, M., Qin, S., Fonseca, L., Sangro, B., Karachiwala, H., . . . Yau, T. (2024). Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. Journal of clinical oncology, 42(17_suppl), LBA4008. https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA4008

Chicago Style (17th ed.) Citation

Decaens, Thomas, et al. "Nivolumab (NIVO) Plus Ipilimumab (IPI) Vs Lenvatinib (LEN) or Sorafenib (SOR) as First-line Treatment for Unresectable Hepatocellular Carcinoma (uHCC): First Results from CheckMate 9DW." Journal of Clinical Oncology 42, no. 17_suppl (2024): LBA4008. https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA4008.

MLA (9th ed.) Citation

Decaens, Thomas, et al. "Nivolumab (NIVO) Plus Ipilimumab (IPI) Vs Lenvatinib (LEN) or Sorafenib (SOR) as First-line Treatment for Unresectable Hepatocellular Carcinoma (uHCC): First Results from CheckMate 9DW." Journal of Clinical Oncology, vol. 42, no. 17_suppl, 2024, p. LBA4008, https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA4008.